The results of Phase III randomised clinical trials have identified several valid treatment options in AGC (ECF, EOX, FLO, DCF, ILF, S-1/cisplatin). Currently, none of these regimens can be declared superior to any of the others since direct comparison between regimens has not yet occurred. Furthermore, if the combination of biological agents with chemotherapy is successful, the efficacy of the aforementioned chemotherapy regimens will need to be considered in a new context. In the meantime, in the absence of a universally accepted standard first-line regimen, the appropriate therapeutic regimens can be selected on the basis of the patient's clinicopathological characteristics (performance status, age, stage of disease, previous treatment). Participation in clinical trials should, of course, be offered to those considered eligible. Recent advances of translational research in gastric cancer have identified prognostic and predictive factors (p53, HER2, ERCC1) which may be used in the future to select combinations of drugs likely to achieve the best results and allow delivery of truly individualised tailored therapy.
|Number of pages||5|
|Journal||Advances in Gastrointestinal Cancers|
|Publication status||Published - 1 Sep 2008|